Tumor entities with a particularly low expression of HMGA2 included prostatic adenocarcinomas (0.4–4%), non-invasive urothelial carcinomas (1.8–4.3%), adenocarcinomas of the breast (1.1–1.5%), and non-Hodgkin’s lymphomas (0%). This evidence concerns the gene HMGA2 and urothelial carcinoma.